Nanoparticles show potential for herpes treatment

August 21, 2012, USA, ( Researchers from Johns Hopkins have demonstrated that Nanoparticles posses the potential to slide through the mucus in animals for direct delivery of the medications to the surfaces of the tissues that require the protection. This is the first time in history that Nanoparticles proved successful for the in vivo treatment approach and currently aim for producing similar drug delivery Nanoparticles to shield humans from sexually transmitted disease (STDs) and also against cancer. The researchers have built mucus-penetrating particles or MPPs that greatly aids in the penetration of the anti-viral drug through the walls of the vagina and provide protection against the herpes infection of the vagina. Justin Hanes, director of Nanomedicine Center, Johns Hopkins University claimed that the research proved for the first time that MPPs posses amazing in vivo potential and can greatly enhance the drug distribution, its retention as well as protection against herpes infection, when a drug is being applied to the mucosal surface. It is a known fact that the body’s mucous surfaces act as the natural defensive system that in addition to keeping the viral infections at bay, also acts as a hindrance to deliver the drug effectively to the targets. The scientists have created the Nanoparticles to deal with the mucous barrier, as these particles mimic the mucous-penetrating viruses on coating with PEG (polyethylene glycol) that makes it easier for them to glide through the mucous surfaces and deposit the drug molecule to the target cells. MPPs are enclosed in a gel and are designed for external application to the vaginal area. For testing the effectiveness of the Nanoparticles formulated drug, the researchers intentionally selected a weak anti-viral drug for herpes treatment and exposed the Nanoparticles formulation to a delirious and infectious viral strain. The scientists discovered that the effectiveness of the MPPs was three times higher than that observed by the normal route of administration, i.e.; the infection prevention profile of normal approach was 16%, while that observed from Nanoparticles measure was 53%. For more: 4th lane, Fontana, California, USA-92337

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.